MX2024007054A - Aglutinantes de mesotelina humana. - Google Patents

Aglutinantes de mesotelina humana.

Info

Publication number
MX2024007054A
MX2024007054A MX2024007054A MX2024007054A MX2024007054A MX 2024007054 A MX2024007054 A MX 2024007054A MX 2024007054 A MX2024007054 A MX 2024007054A MX 2024007054 A MX2024007054 A MX 2024007054A MX 2024007054 A MX2024007054 A MX 2024007054A
Authority
MX
Mexico
Prior art keywords
human mesothelin
binders
mesothelin binders
human
antigen
Prior art date
Application number
MX2024007054A
Other languages
English (en)
Spanish (es)
Inventor
Arthur Fridman
Chung - Ming HSIEH
Masahisa Handa
Sujata Singh
Sahba Tabrizifard
Sandra Isabel Vanegas
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2024007054A publication Critical patent/MX2024007054A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024007054A 2021-12-10 2022-12-09 Aglutinantes de mesotelina humana. MX2024007054A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163288162P 2021-12-10 2021-12-10
PCT/US2022/081253 WO2023108114A2 (en) 2021-12-10 2022-12-09 Human mesothelin binders

Publications (1)

Publication Number Publication Date
MX2024007054A true MX2024007054A (es) 2024-09-04

Family

ID=86731328

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007054A MX2024007054A (es) 2021-12-10 2022-12-09 Aglutinantes de mesotelina humana.

Country Status (8)

Country Link
EP (1) EP4444757A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025501452A (cg-RX-API-DMAC7.html)
KR (1) KR20240114766A (cg-RX-API-DMAC7.html)
CN (1) CN118660911A (cg-RX-API-DMAC7.html)
AU (1) AU2022407541A1 (cg-RX-API-DMAC7.html)
CA (1) CA3239553A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024007054A (cg-RX-API-DMAC7.html)
WO (1) WO2023108114A2 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150074T1 (hr) * 2007-10-01 2015-03-13 Bristol-Myers Squibb Company Humana antitijela koja se vežu za mezotelin i njihove uporabe
AU2011349443B2 (en) * 2010-12-20 2015-12-24 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
US10730954B2 (en) * 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
CN114008071B (zh) * 2018-12-27 2025-01-21 吉加根公司 抗ctla-4结合蛋白及其使用方法
CN114585416B (zh) * 2019-04-01 2025-01-17 莱克制药股份有限公司 用于调节免疫应答和治疗疾病的btla结合(cd272)抗体

Also Published As

Publication number Publication date
EP4444757A2 (en) 2024-10-16
AU2022407541A1 (en) 2024-06-13
KR20240114766A (ko) 2024-07-24
JP2025501452A (ja) 2025-01-22
WO2023108114A2 (en) 2023-06-15
WO2023108114A3 (en) 2024-04-04
CA3239553A1 (en) 2023-06-15
CN118660911A (zh) 2024-09-17
EP4444757A4 (en) 2026-04-15

Similar Documents

Publication Publication Date Title
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
MX2025000260A (es) Proteina de union al antigeno anti-steap1
SA520420631B1 (ar) الأجسام المضادة لـ cd3 واستخداماتها
PH12022550348A1 (en) Materials and methods for improved single chain variable fragments
ZA201906004B (en) Anti-par2 antibodies and uses thereof
PH12021500031A1 (en) Anti-il2 receptor gamma antigen-binding proteins
MX2020012905A (es) Proteínas de unión multiespecíficas y mejoras con estas.
MX2022011732A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
DK3638698T3 (da) Anti-TMPRSS2-antistoffer og antigenbindingsfragmenter
GEP20227440B (en) Anti-ilt4 antibodies and antigen-binding fragments
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
WO2020014473A8 (en) TGFβ1 INHIBITORS AND USE THEREOF
MX2021007093A (es) Anticuerpos btla.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
ZA202309150B (en) Antibody against nkp46 and application of antibody
HRP20260098T1 (hr) Anti-gprc5d monoklonska protutijela i njihova upotreba
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.
MX2023012300A (es) Anticuerpos humanos contra artemina y metodos de uso de estos.
MX2024014547A (es) Anticuerpos anti-bcma
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.